Neutrophil Extracellular Traps Associate with Clinical Stages in Breast Cancer

Rivera-Franco, Mónica M.; Torres-Ruíz, Jiram; Gómez‐Martín, Diana; Anglès-Cano, Eduardo; Sevilla-González, María de la Luz

doi:10.1007/s12253-019-00763-5

Cited by 25 publications

(22 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, elevated NET levels, measured as serum MPO-DNA molecules, correlates with metastatic phenotype of colorectal cancer patients [27]. Moreover, the levels of circulating NE-DNA complexes increased with the stage of the disease in breast and gastric cancers [28,29]. Increased levels of plasma biomarkers of activated neutrophils and NETs, such as cfDNA, NE and citH3, have also recently been detected in a mouse model of pancreatic cancer [30].…”

Section: Nets In Cancer As Diagnostic and Predictive Useful Biomarkersmentioning

confidence: 99%

Neutrophil extracellular traps in cancer: not only catching microbes

Ronchetti

Boubaker

Barba

et al. 2021

J Exp Clin Cancer Res

View full text Add to dashboard Cite

Neutrophils are the most abundant type of white blood cells circulating throughout the bloodstream and are often considered the frontline defenders in innate immunity. However, neutrophils are increasingly being recognized as having an important role in tumorigenesis and carcinogenesis due to their aberrant activation by molecules released into the tumor microenvironment. One defensive response of neutrophils that is aberrantly triggered during the neoplastic process is called NETosis, where activated neutrophils expel their DNA and intracellular contents in a web-like structure known as a neutrophil extracellular trap (NET). In cancer, NETosis has been linked to increased disease progression, metastasis, and complications such as venous thromboembolism. NET structures released by neutrophils can also serve as a scaffold for clot formation, shining new light on the role of neutrophils and NETosis in coagulation-mediated diseases.Here, we review current available knowledge regarding NET and the related NETosis process in cancer patients, with an emphasis on pre-clinical and clinical data fostering the identification and validation of biomarkers of NET with a predictive/prognostic role in cancer patients treated with immunotherapy agents. NETosis biomarkers, e.g., citH3, may integrate correlates of immunogenicity currently available (e.g., PD-L1 expression, TMB, TILs) and help select the subsets of patients who may most benefit from the use of the therapeutic weapons under discussion.

show abstract

Section: Nets In Cancer As Diagnostic and Predictive Useful Biomarkersmentioning

confidence: 99%

Neutrophil extracellular traps in cancer: not only catching microbes

Ronchetti

Boubaker

Barba

et al. 2021

J Exp Clin Cancer Res

View full text Add to dashboard Cite

show abstract

“…Furthermore, it was found that the levels of NE-DNA complexes in serum of breast cancer patients correlate with the stage of the disease. Higher levels of NE-DNA complexes were observed in regional and metastatic disease [130]. Interestingly, NET formation was reported in a connection to a high-risk luminal A breast cancer subtype, with increased cell mobility, cancer-stem-cell-like features and hormonal signaling, but decreased proliferation and dysfunctional immune response [131].…”

Section: Neutrophil Extracellular Trapsmentioning

confidence: 99%

How to Predict Metastasis in Luminal Breast Cancer? Current Solutions and Future Prospects

Tabor

Szostakowska-Rodzoś

Fabisiewicz

et al. 2020

IJMS

View full text Add to dashboard Cite

Breast cancer metastasis is the main cause of breast cancer mortality. Luminal breast cancer represents the majority of breast cancer cases and, despite relatively good prognosis, its heterogeneity creates problems with a proper stratification of patients and correct identification of the group with a high risk of metastatic relapse. Current prognostic tools are based on the analysis of the primary tumor and, despite their undisputed power of prediction, they might be insufficient to foresee the relapse in an accurate and precise manner, especially if the relapse occurs after a long period of dormancy, which is very common in luminal breast cancer. New approaches tend to rely on body fluid analyses, which have the advantage of being non-invasive and versatile and may be repeated and used for monitoring the disease in the long run. In this review we describe the current, newly-developed, and only-just-discovered methods which are or may become useful in the assessment of the probability of the relapse.

show abstract

“…NETs are also considered as a predictive biomarker for multi‐cancers. However, it is questioned whether NETs and NETs‐associated factors have the specificity for disease categories, phenomes, severities, stages, durations, metastasis, and responses to drugs as criteria for disease‐specific biomarkers 8‐14 . Cancer‐associated factors appear during the development of new NETs‐targeted therapies (Figure 1) and is evidenced by preclinical cancer models and clinical cancer patients.…”

Section: Figurementioning

confidence: 99%

“…However, it is questioned whether NETs and NETs-associated factors have the specificity for disease categories, phenomes, severities, stages, durations, metastasis, and responses to drugs as criteria for disease-specific biomarkers. [8][9][10][11][12][13][14] Cancer-associated factors appear during the development of new NETs-targeted therapies (Figure 1) and is evidenced by preclinical cancer models and clinical cancer patients. It is proposed that anti-DAMPs, anti-postoperative inflammation, inflammatory/pyroptosis signals, immunotherapy with surgery, antiangiogenesis, and targeted therapies for neutrophils, macrophages, MDSCs, and Tregs could be a new therapeutic strategy to reduce cellular immunity impairment after surgery.…”

mentioning

confidence: 99%